In the second part of our interview with Fadi Haddad, MD, an assistant professor and co-leader of the Section of Chronic ...

The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a ...

Crucially, the analysis demonstrated that less invasive procedures like TAD/SLNB/TLNB are noninferior to ALND in terms of axillary recurrence based on the lower bound of a 90% confidence interval ...

Initial breast surgery was initial BCS in 91.2% of the MRI arm and 92.7% of the no MRI arm; axillary surgery was sentinel lymph node biopsy alone in 86.4% and 94.7%, respectively; final margin status ...

Abemaciclib monotherapy benefited 33% of patients with HR-positive, HER2-negative breast cancer post-CDK4/6 inhibitor progression. Abemaciclib shows promise as a monotherapy for HR-positive, ...

Sacituzumab govitecan maintained physical functioning scores, contrasting with chemotherapy's deterioration in advanced TNBC patients. Time to deterioration in fatigue was comparable between ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

Factors associated with higher progression rates included double-hit/triple-hit lymphoma, high IPI status, and primary refractory disease. A recent study reveals critical insights on disease ...

Tucatinib addition to trastuzumab and pertuzumab significantly improved PFS in HER2-positive metastatic breast cancer, with a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...

T-DXd plus pertuzumab improved quality-of-life outcomes, with fewer skin and mucosal symptoms but more gastrointestinal issues compared to the standard regimen. Both treatment arms showed similar pain ...